ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Total Current Assets
All assets expected to be converted to cash or used up within one year.
ProQR Therapeutics N.V.NASDAQ: PRQR
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 41.6% from a year ago
Total current assets stood at €87.07M at the end of Q1 FY2026, down 41.6% from a year earlier and down 13.0% from the prior quarter. Over 3 fiscal years it compounded at -13.5% a year.
Context
- Total current assets amounted to 87.8% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -41.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
EUR · from the balance sheet
- Latest · FY2025
- 100.08M EUR
- Year-over-year change
- -34.9%
- 4-year CAGR
- -15.0%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.08M | -34.9% |
| FY2024 | 2024-12-31 | 153.85M | +15.1% |
| FY2023 | 2023-12-31 | 133.65M | -13.5% |
| FY2022 | 2022-12-31 | 154.46M | -19.3% |
| FY2021 | 2021-12-31 | 191.48M | — |
Total Current Assets vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -41.6% is the 10th highest of 11, against a peer median of -20.9%.
- Total current assets amounts to 87.8% of total assets for PRQR, versus a peer median of 87.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $293.17M USD | -28.1% | -12.6% | 67.6% | |
| Mar 2026 | $283.09M USD | +93.6% | +96.0% | 86.8% | |
| Mar 2026 | $273.29M USD | -6.3% | -21.3% | 69.0% | |
| Mar 2026 | $266.87M USD | -33.8% | +13.4% | 79.5% | |
ZURAZura Bio Limited | Mar 2026 | $227M USD | +32.2% | +298.4% | 99.3% |
| Mar 2026 | $216.88M USD | -22.2% | -15.7% | 88.4% | |
| Dec 2025 | A$139.79M AUD | -19.6% | +18.0% | 95.0% | |
| Mar 2026 | $128.07M USD | -43.0% | -22.8% | 85.8% | |
| Mar 2026 | €87.07M EUR | -41.6% | -13.5% | 87.8% | |
| Mar 2026 | $40.03M USD | -40.2% | -15.7% | 98.6% | |
| Mar 2026 | $31.06M USD | +24.2% | +13.4% | 93.8% | |
| Peer median (excluding PRQR) | — | -20.9% | +0.4% | 87.6% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 187.52M | 94.78M | 131.37M | 149.41M | 92.37M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 823K | 56.25M | 1.4M | 2.03M | 5.08M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 823K | 982K | 0 | 2.03M | 0 |
| Total Current Assets | 191.48M | 154.46M | 133.65M | 153.85M | 100.08M |
| Property, Plant & Equipment (Net) | 17.47M | 16.24M | 18.67M | 14.11M | 12.62M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 629K | 621K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 1 | 0 | 0 | 0 |
| Total Non-current Assets | 18.1M | 16.86M | 18.67M | 14.11M | 12.62M |
| Total Assets | 209.58M | 171.32M | 152.31M | 167.96M | 112.71M |
| Account Payables | 191K | 392K | 1.7M | 16K | 297.87K |
| Short-term Debt | 4.77M | 2.5M | 1.78M | 4.58M | 4.44M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 22.72M | 0 | 17.54M |
| Other Current Liabilities | 19.87M | 15.59M | 11.58M | 31.26M | 10.14M |
| Total Current Liabilities | 27.6M | 20.99M | 37.78M | 38.9M | 32.43M |
| Long-term Debt | 39.32M | 4.27M | 4.74M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 48.79M | 0 | 21.38M |
| Other Non-current Liabilities | 14.69M | 65.57M | 0 | 29.43M | 0 |
| Total Non-current Liabilities | 68.75M | 83.65M | 68.81M | 40.5M | 30.93M |
| Total Liabilities | 96.35M | 104.64M | 106.59M | 79.4M | 63.36M |
| Common Stock | 3M | 3.37M | 3.72M | 4.31M | 4.31M |
| Retained Earnings | (317.77M) | (379.11M) | (442.8M) | (427.16M) | (467.31M) |
| Accumulated OCI | 30.3M | 30.26M | 28.69M | 27.6M | 28.68M |
| Other Stockholders Equity | 1 | 1 | 0 | 0 | 0 |
| Minority Interest | (604K) | (384K) | 0 | 0 | 0 |
| Total Equity | 113.23M | 66.68M | 45.72M | 88.56M | 49.35M |
| Total Debt | 60.37M | 21.97M | 21.8M | 17.22M | 13.99M |
| Net Debt | (127.15M) | (72.8M) | (109.57M) | (132.19M) | (78.39M) |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.